Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Characterization of a causative mutation of hemophilia A identified in the promoter region of the factor VIII gene (F8).

Dai L, Cutler JA, Savidge GF, Mitchell MJ.

J Thromb Haemost. 2008 Jan;6(1):193-5. Epub 2007 Oct 16. No abstract available.

2.

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

Moore GW, Rangarajan S, Savidge GF.

Clin Appl Thromb Hemost. 2008 Jul;14(3):332-7. Epub 2007 Sep 25.

PMID:
17895508
3.

Characterisation of five factor XI mutations.

Mitchell MJ, Dai L, Clarke JB, Bolton-Maggs PH, Savidge GF, Alhaq A.

Thromb Haemost. 2007 Jun;97(6):884-9.

PMID:
17549289
4.

Diagnostic and therapeutic difficulties in type 2A von Willebrand disease: resolution.

Thomas MR, Cutler JA, Savidge GF.

Clin Appl Thromb Hemost. 2006 Apr;12(2):237-9.

PMID:
16708129
8.

The significance of published polymorphisms in 14 cases of mild factor VII deficiency.

Cutler JA, Patel R, Mitchell MJ, Savidge GF.

Blood Coagul Fibrinolysis. 2005 Mar;16(2):91-5.

PMID:
15741795
9.

Determination of the urinary aglycone metabolites of vitamin K by HPLC with redox-mode electrochemical detection.

Harrington DJ, Soper R, Edwards C, Savidge GF, Hodges SJ, Shearer MJ.

J Lipid Res. 2005 May;46(5):1053-60. Epub 2005 Feb 1.

10.

Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash.

Lee AP, Boyle CA, Savidge GF, Fiske J.

Br Dent J. 2005 Jan 8;198(1):33-8; discussion 26.

PMID:
15716891
11.

Superwarfarin poisoning.

Pavlu J, Harrington DJ, Voong K, Savidge GF, Jan-Mohamed R, Kaczmarski R.

Lancet. 2005 Feb 12-18;365(9459):628. No abstract available.

PMID:
15708110
12.

Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.

Moore GW, Kamat AV, Gurney DA, O'Connor O, Rangarajan S, Carr R, Savidge GF.

Clin Lab Haematol. 2004 Dec;26(6):429-34.

PMID:
15596003
13.

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.

Stieltjes N, Altisent C, Auerswald G, Négrier C, Pouzol P, Reynaud J, Roussel-Robert V, Savidge GF, Villar A, Schulman S.

Haemophilia. 2004 Sep;10(5):452-8.

PMID:
15357770
14.

Germline mosaicism resulting in the transmission of severe hemophilia B from a grandfather with a mild deficiency.

Cutler JA, Mitchell MJ, Smith MP, Savidge GF.

Am J Med Genet A. 2004 Aug 15;129A(1):13-5.

PMID:
15266608
15.

More on: unusual expression of the F9 gene in peripheral lymphocytes hinders investigation of F9 mRNA in hemophilia B patients.

Cutler JA, Mitchell MJ, Savidge GF.

J Thromb Haemost. 2004 Jun;2(6):1021. No abstract available.

16.
17.

Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.

Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J.

Am J Obstet Gynecol. 2004 Feb;190(2):495-501.

PMID:
14981396
18.

Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia.

Shmeleva VM, Kapustin SI, Papayan LP, Sobczyńska-Malefora A, Harrington DJ, Savidge GF.

Thromb Res. 2003;111(6):351-6.

PMID:
14698652
19.

Hyperhomocysteinemia and B-vitamin status after discontinuation of oral anticoagulation therapy in patients with a history of venous thromboembolism.

Sobczyńska-Malefora A, Harrington DJ, Rangarajan S, Kovacs JA, Shearer MJ, Savidge GF.

Clin Chem Lab Med. 2003 Nov;41(11):1493-7.

PMID:
14656031
20.

Glanzmann's thrombasthenia proposed optimal management during surgery and delivery.

Bell JA, Savidge GF.

Clin Appl Thromb Hemost. 2003 Apr;9(2):167-70.

PMID:
12812388
21.

Genetic variations observed in arterial and venous thromboembolism--relevance for therapy, risk prevention and prognosis.

Harrington DJ, Malefora A, Schmeleva V, Kapustin S, Papayan L, Blinov M, Harrington P, Mitchell M, Savidge GF.

Clin Chem Lab Med. 2003 Apr;41(4):496-500.

PMID:
12747593
22.
23.
24.

Nanofiltration of single plasma donations: feasibility study.

Burnouf T, Radosevich M, El-Ekiaby M, Satoh S, Sato T, Amin SN, Savidge GF, Goubran HA.

Vox Sang. 2003 Feb;84(2):111-9.

PMID:
12609017
25.

Evaluation of an automated screening assay for von Willebrand disease type 2N.

Taylor SL, Bromidge E, Savidge GF, Alhaq A.

Clin Lab Haematol. 2002 Dec;24(6):369-75.

PMID:
12452818
26.

Under-representation of the -455A beta-fibrinogen allele in survivors of pulmonary embolism.

Kapustin SI, Blinov MN, Papayan LP, Imyanitov EN, Mitchell MJ, Savidge GF.

Thromb Res. 2002 Apr 1;106(1):89-90. No abstract available.

PMID:
12165294
27.

Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity.

Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K, Aziz S, Cardona C, Hammond WP, Savidge GF, Rafii S, Sobel M.

Circ Res. 2002 Jul 12;91(1):25-31.

PMID:
12114318
28.
29.
30.

The identification and classification of 41 novel mutations in the factor VIII gene (F8C).

Cutler JA, Mitchell MJ, Smith MP, Savidge GF.

Hum Mutat. 2002 Mar;19(3):274-8.

PMID:
11857744
31.
32.

Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies.

Patel RK, Savidge GF, Rangarajan S.

Br J Haematol. 2001 Jul;114(1):245-6. No abstract available.

PMID:
11472380
33.

A rapid and cost-effective method for analysis of three common genetic risk factors for thrombosis.

Cutler JA, Mitchell MJ, Greenslade K, Smith MP, Savidge GF.

Blood Coagul Fibrinolysis. 2001 Jan;12(1):33-6.

PMID:
11229824
34.

Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation.

Nishibe T, Parry G, Ishida A, Aziz S, Murray J, Patel Y, Rahman S, Strand K, Saito K, Saito Y, Hammond WP, Savidge GF, Mackman N, Wijelath ES.

Blood. 2001 Feb 1;97(3):692-9.

35.

Improved detection of lupus anticoagulants by the dilute Russell's Viper venom time.

Moore GW, Savidge GF, Smith MP.

Blood Coagul Fibrinolysis. 2000 Dec;11(8):767-74.

PMID:
11132656
36.

Characterisation of a prothrombinase activator on the hepatoma derived cell-line, PLC/PRF/5.

Leach ME, Bolton P, Sethi M, Savidge GF, Alhaq A.

Biochem Soc Trans. 1998 Feb;26(1):S14. No abstract available.

PMID:
10909772
37.

Rapid genetic diagnosis in neonatal pulmonary artery thrombosis caused by homozygous antithrombin Budapest 3.

Brown SA, Mitchell M, Cutler JA, Moore G, Smith MP, Savidge GF.

Clin Appl Thromb Hemost. 2000 Jul;6(3):181-3.

PMID:
10898281
38.
39.

Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis.

Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ.

Blood Coagul Fibrinolysis. 1999 Jan;10(1):25-31.

PMID:
10070832
40.

Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.

Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF.

Thromb Haemost. 1999 Jan;81(1):35-8.

PMID:
9974371
41.

Acquired haemophilia A: errors in the diagnosis.

Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF.

Blood Coagul Fibrinolysis. 1998 Oct;9(7):623-8.

PMID:
9863711
43.

Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes.

Robinson MS, Mackie IJ, Khair K, Liesner R, Goodall AH, Savidge GF, Machin SJ, Harrison P.

Br J Haematol. 1998 Feb;100(2):351-7.

PMID:
9488626
44.
45.

Megakaryocytes and platelets in alpha-granule disorders.

Smith MP, Cramer EM, Savidge GF.

Baillieres Clin Haematol. 1997 Feb;10(1):125-48. Review.

PMID:
9154319
46.

Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease.

Smith MP, Rice KM, Bromidge ES, Lawn M, Beresford-Webb R, Spence K, Khair K, Hann I, Savidge GF.

Blood Coagul Fibrinolysis. 1997 Jan;8(1):6-12.

PMID:
9105631
47.

Recombinant factor VIIa (r-FVIIa) in haemophilia management.

Rice KM, Savidge GF.

Transfus Sci. 1996 Sep;17(3):339-40. No abstract available.

PMID:
10184611
48.

Continuous infusion of factor VIII for surgery and major bleeding.

Hay CR, Doughty HI, Savidge GF.

Blood Coagul Fibrinolysis. 1996 Mar;7 Suppl 1:S15-9.

PMID:
8735792
49.

NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.

Rice KM, Savidge GF.

Haemostasis. 1996;26 Suppl 1:131-4.

PMID:
8904187
50.

Assay of protein S in systemic lupus erythematosus.

Lawrie AS, Lloyd ME, Mohamed F, Irons S, Hughes GR, Savidge GF.

Blood Coagul Fibrinolysis. 1995 Jun;6(4):322-4.

PMID:
7548680

Supplemental Content

Loading ...
Support Center